Thomas S. McHugh net worth and biography

Thomas McHugh Biography and Net Worth

Thomas McHugh was appointed Chief Financial Officer in December 2019. Prior to joining Avadel, Tom served as Senior Vice President of Finance of Ironshore Pharmaceuticals Inc., where he built and led the US finance, accounting, and treasury functions and supported Ironshore's new product launch. Before his time at lronshore, Tom was the Chief Financial Officer and Treasurer at Lumara Health, a specialty branded pharmaceutical company focused on women's health. While at Lumara he supported a number of key strategic initiatives, including a new product launch, a restructuring, and a sale of the company. Prior to joining Lumara, Tom was a Managing Director and Global Controller at BearingPoint, a global consultancy, and prior to that, served as Chief Financial Officer at Huttig Building Products, Inc. Tom began his career in public accounting at PricewaterhouseCoopers. He earned his bachelor's degree in finance from Bentley University and a master's degree in accounting from Northeastern University.

What is Thomas S. McHugh's net worth?: The estimated net worth of Thomas S. McHugh is at least $1.87 million as of December 13th, 2024. Mr. McHugh owns 87,800 shares of Avadel Pharmaceuticals stock worth more than $1,874,530 as of December 5th. This net worth estimate does not reflect any other assets that Mr. McHugh may own. Additionally, Mr. McHugh receives a salary of $663,140.00 as CFO at Avadel Pharmaceuticals. Learn More about Thomas S. McHugh's net worth.
How old is Thomas S. McHugh?: Mr. McHugh is currently 59 years old. There are 4 older executives and no younger executives at Avadel Pharmaceuticals. Learn More on Thomas S. McHugh's age.
What is Thomas S. McHugh's salary?: As the CFO of Avadel Pharmaceuticals PLC., Mr. McHugh earns $663,140.00 per year. There are 3 executives that earn more than Mr. McHugh. The highest earning executive at Avadel Pharmaceuticals is Mr. Gregory J. Divis Jr., CEO & Director, who commands a salary of $985,200.00 per year. Learn More on Thomas S. McHugh's salary.
How do I contact Thomas S. McHugh?: The corporate mailing address for Mr. McHugh and other Avadel Pharmaceuticals executives is 10 EARLSFORT TERRACE, DUBLIN L2, D02. Avadel Pharmaceuticals can also be reached via phone at (531) 901-5201 and via email at [email protected]. Learn More on Thomas S. McHugh's contact information.
Has Thomas S. McHugh been buying or selling shares of Avadel Pharmaceuticals?: Thomas S. McHugh has not been actively trading shares of Avadel Pharmaceuticals over the course of the past ninety days. Most recently, on Friday, December 13th, Thomas S. Mchugh bought 2,300 shares of Avadel Pharmaceuticals stock. The stock was acquired at an average cost of $10.44 per share, with a total value of $24,012.00. Following the completion of the transaction, the chief financial officer now directly owns 87,800 shares of the company's stock, valued at $916,632. Learn More on Thomas S. McHugh's trading history.
Who are Avadel Pharmaceuticals' active insiders?: Avadel Pharmaceuticals' insider roster includes Gregory Divis (CEO), Geoffrey Glass (Director), Geoffrey Glass (Director), Thomas McHugh (CFO), Linda Palczuk (Director), and Peter Thornton (Director). Learn More on Avadel Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Avadel Pharmaceuticals?: During the last twelve months, Avadel Pharmaceuticals insiders bought shares 8 times. They purchased a total of 55,579 shares worth more than $526,363.04. The most recent insider tranaction occured on January, 21st when Director Linda Palczuk bought 5,000 shares worth more than $39,650.00. Insiders at Avadel Pharmaceuticals own 5.2% of the company. Learn More about insider trades at Avadel Pharmaceuticals.
Information on this page was last updated on 1/21/2025.

Thomas S. McHugh Insider Trading History at Avadel Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/13/2024	Buy	2,300	$10.44	$24,012.00	87,800
12/11/2024	Buy	5,000	$10.49	$52,450.00	85,500
1/16/2024	Buy	2,000	$14.50	$29,000.00	80,500
8/14/2023	Buy	2,000	$14.45	$28,900.00	78,500
11/29/2022	Buy	5,000	$7.80	$39,000.00	76,500
5/27/2022	Buy	50,000	$2.14	$107,000.00	71,500
9/18/2020	Buy	4,000	$6.00	$24,000.00	21,500
8/13/2020	Buy	10,000	$7.78	$77,800.00	10,000

Thomas S. McHugh Buying and Selling Activity at Avadel Pharmaceuticals

Avadel Pharmaceuticals Company Overview

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Today's Range

Now: $21.35

$21.32

$21.40

50 Day Range

MA: $18.47

$14.00

$23.56

2 Week Range

Now: $21.35

$6.38

$23.57

Volume

2,524,779 shs

Average Volume

2,716,553 shs

Market Capitalization

$2.09 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26

Thomas McHugh Biography and Net Worth

What is Thomas S. McHugh's net worth?

How old is Thomas S. McHugh?

What is Thomas S. McHugh's salary?

How do I contact Thomas S. McHugh?

Has Thomas S. McHugh been buying or selling shares of Avadel Pharmaceuticals?

Who are Avadel Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Avadel Pharmaceuticals?